Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Receivables (2018 - 2024)

Abvc Biopharma (ABVC) has disclosed Receivables for 8 consecutive years, with $3483.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Receivables fell 99.44% year-over-year to $3483.0, compared with a TTM value of $3483.0 through Sep 2024, down 99.44%, and an annual FY2023 reading of $749103.0, down 41.07% over the prior year.
  • Receivables was $3483.0 for Q3 2024 at Abvc Biopharma, up from $3440.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.6 million in Q4 2023 and bottomed at $3440.0 in Q2 2024.
  • Average Receivables over 5 years is $410953.0, with a median of $426091.0 recorded in 2021.
  • The sharpest move saw Receivables surged 1212.72% in 2023, then tumbled 99.44% in 2024.
  • Year by year, Receivables stood at $303147.0 in 2020, then skyrocketed by 40.56% to $426091.0 in 2021, then skyrocketed by 198.33% to $1.3 million in 2022, then grew by 24.89% to $1.6 million in 2023, then plummeted by 99.78% to $3483.0 in 2024.
  • Business Quant data shows Receivables for ABVC at $3483.0 in Q3 2024, $3440.0 in Q2 2024, and $4083.0 in Q1 2024.